Sonja Lang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/340030/publications.pdf

Version: 2024-02-01

32	1,837	17 h-index	32
papers	citations		g-index
32	32	32	1750 citing authors
all docs	docs citations	times ranked	

#	Article	IF	Citations
1	Machine Learning Applied to Omics Datasets Predicts Mortality in Patients with Alcoholic Hepatitis. Metabolites, 2022, 12, 41.	2.9	6
2	Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. Hepatology International, 2022, 16, 359-370.	4.2	15
3	The fecal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 788-799.	3.7	66
4	Uncontrolled hypertension: A neglected risk in patients with NAFLD. Journal of Internal Medicine, 2022, 292, 162-164.	6.0	2
5	Intestinal virome in patients with alcohol use disorder and after abstinence. Hepatology Communications, 2022, 6, 2058-2069.	4.3	18
6	Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Current Atherosclerosis Reports, 2022, 24, 533-546.	4.8	19
7	Perinatal Obesity Induces Hepatic Growth Restriction with Increased DNA Damage Response, Senescence, and Dysregulated Igf-1-Akt-Foxo1 Signaling in Male Offspring of Obese Mice. International Journal of Molecular Sciences, 2022, 23, 5609.	4.1	5
8	NAFLD and cardiovascular diseases: a clinical review. Clinical Research in Cardiology, 2021, 110, 921-937.	3.3	285
9	The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. Translational Research, 2021, 227, 1-14.	5.0	13
10	Targeting pathobionts for the treatment of alcoholâ€associated liver disease. Liver International, 2021, 41, 239-240.	3.9	1
11	Hypertension in NAFLD: An uncontrolled burden. Journal of Hepatology, 2021, 74, 1258-1260.	3.7	11
12	Combined analysis of gut microbiota, diet and <i>PNPLA3</i> polymorphism in biopsyâ€proven nonâ€alcoholic fatty liver disease. Liver International, 2021, 41, 1576-1591.	3.9	11
13	Maternal Exercise Mediates Hepatic Metabolic Programming via Activation of AMPK-PGC1 \hat{l}_{\pm} Axis in the Offspring of Obese Mothers. Cells, 2021, 10, 1247.	4.1	15
14	Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. Frontiers in Physiology, 2021, 12, 699253.	2.8	45
15	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology, 2020, 71, 522-538.	7.3	151
16	The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. Journal of Hepatology, 2020, 72, 391-400.	3.7	119
17	Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. Gut Microbes, 2020, 12, 1785251.	9.8	60
18	Transcriptomic Profiling Identifies Novel Hepatic and Intestinal Genes Following Chronic Plus Binge Ethanol Feeding in Mice. Digestive Diseases and Sciences, 2020, 65, 3592-3604.	2.3	11

#	Article	IF	CITATIONS
19	Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Coâ€Metabolism in Patients With Alcoholic Hepatitis. Hepatology Communications, 2020, 4, 1168-1182.	4.3	22
20	Microbiota and Fatty Liver Diseaseâ€"the Known, the Unknown, and the Future. Cell Host and Microbe, 2020, 28, 233-244.	11.0	115
21	Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming. Scientific Reports, 2020, 10, 15424.	3.3	18
22	Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. Frontiers in Physiology, 2020, 11, 370.	2.8	11
23	Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools. Scientific Reports, 2020, 10, 9385.	3.3	20
24	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2020, 159, 1839-1852.	1.3	103
25	Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology, 2020, 72, 2182-2196.	7.3	74
26	Cytolysinâ€positive <i>Enterococcus faecalis</i> is not increased in patients with nonâ€alcoholic steatohepatitis. Liver International, 2020, 40, 860-865.	3.9	29
27	Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survival. Scandinavian Journal of Gastroenterology, 2020, 55, 222-227.	1.5	6
28	Phenotyping nonâ€alcoholic fatty liver disease by the gut microbiota: Ready for prime time?. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1969-1977.	2.8	27
29	High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. Hepatology Communications, 2020, 4, 681-695.	4.3	28
30	Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. Digestive Diseases and Sciences, 2019, 64, 1878-1892.	2.3	35
31	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575, 505-511.	27.8	493
32	Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B. European Journal of Gastroenterology and Hepatology, 2017, 29, 1235-1240.	1.6	3